News & analysis on the clinical development and manufacture of large molecule drugs
By Natalie Morrison
- Last updated on
Kobrin joins the firm as it pushes to establish itself in the global biopharma market.
He was previously chief medical officer and chairman of the strategic and portfolio board at Actelion.
Of Immune, Kobrin commented: “I am very impressed with the Company's research and development platforms which include Bertilimumab, a first-in-class fully human monoclonal antibody against eotaxin-1 ready to enter phase II in multiple indications and the innovative Antibody Drug Conjugate technology of NanoMabs that could significantly improve the efficacy and safety of anti-cancer and anti-inflammatory drugs.”